Document Detail


Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.
MedLine Citation:
PMID:  15004324     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study was designed to confirm or negate findings from earlier trials demonstrating that Colostrinin, a novel compound derived from ewes' colostrum, has potential in the treatment of mild or moderate Alzheimer's Disease (AD). 105 patients were recruited from six psychiatric centres in Poland. The trial consisted of a 15 week double-blind phase comparing Colostrinin with placebo, followed by a second 15 week open labelled phase when all patients received Colostrinin. The dosage of Colostrinin was 100 microg on alternate days for three weeks followed by two weeks drug-free. This cycle was repeated three times for each phase. The primary outcome measures used were Alzheimer's Disease Assessment Scale-cognitive portion (ADAS-cog) and Clinical Global Impression of Change (CGIC). Secondary outcome measures were Instrumental Activities of Daily Living (IADL); Mini-Mental State Examination (MMSE); ADAS-non cognitive test (ADAS-non cog); and overall Patient Response. The main outcome measures were assessed at week 15 when active was compared with placebo but all parameters were evaluated at baseline, week 15 and week 30. Two separate statistical analyses were undertaken, a Full Sample Analysis (FSA) in which all missing values were replaced with the worst result observed and a Valid for Efficacy (VFE) analysis in which those patients who had serious protocol violations were excluded. This resulted in 14 patients being excluded from the VFE-analysis. The FSA analysis at week 15 showed a stabilizing effect of Colostrinin on cognitive function in ADAS-cog (p = 0.02) and on daily function in IADL (p = 0.02). The overall patient response was also in favour of the active (p = 0.03). Patients graded as mild on entry also showed a superior response of ADAS-cog compared with more advanced cases (p = 0.01). Evidence from this study indicates an early beneficial effect on cognitive symptoms and daily function. Colostrinin has potential value in the treatment AD.
Authors:
A Bilikiewicz; W Gaus
Related Documents :
12390444 - Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country,...
17664404 - Galantamine treatment of vascular dementia: a randomized trial.
9236954 - The spanish instrument protocol: design and implementation of a study to evaluate treat...
8564324 - Further evidence that reading ability is not preserved in alzheimer's disease.
25178954 - The mediating role of disgust sensitivity and thought-action fusion between religiosity...
16845354 - Active involvement and intervention in patients exposed to whiplash trauma in automobil...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of Alzheimer's disease : JAD     Volume:  6     ISSN:  1387-2877     ISO Abbreviation:  J. Alzheimers Dis.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-03-08     Completed Date:  2004-09-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9814863     Medline TA:  J Alzheimers Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  17-26     Citation Subset:  IM    
Affiliation:
Clinic for Psychiatric Diseases, Medical University of Gdansk, Gdansk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activities of Daily Living / classification
Aged
Alzheimer Disease / diagnosis,  drug therapy*,  psychology
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Geriatric Assessment / statistics & numerical data
Humans
Male
Mental Status Schedule / statistics & numerical data
Middle Aged
Neuropsychological Tests / statistics & numerical data
Nootropic Agents / adverse effects,  therapeutic use*
Peptides / adverse effects,  therapeutic use*
Poland
Psychometrics
Treatment Outcome
Chemical
Reg. No./Substance:
0/Nootropic Agents; 0/Peptides; 0/colostrinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dement...
Next Document:  Apple juice prevents oxidative stress induced by amyloid-beta in culture.